Загрузка...
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease characterized by uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage. We evaluated the effect of terminal complement blockade with the anti-C5 monoclonal antibody eculiz...
Сохранить в:
| Опубликовано в: : | Blood |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ https://ncbi.nlm.nih.gov/pubmed/25833956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-600411 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|